LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
604 IndexCholangiocarcinoma (Contd.)
clonorchis sinensis infestation
and, 253
primary biliary cirrhosis and,
253, 257
primary sclerosing cholangitis
and, 253
risk factor of, 253, 258
Cholecystography, 172
Choriocarcinoma, 297, 301
Chromosome 3p allele loss, in lung
cancer, 205, 210
Chronic hepatitis C infection
HCC development in, 256, 260
African American ethnicity,
256, 260
esophageal varices, 256, 260
smoking, 256, 260
Chronic lymphocytic leukemia
(CLL), 9, 517, 522
Chronic myeloid leukemia (CML),
449
allogeneic hematopoietic stem cell
transplantation in, 450, 454
ASCT in, 450, 453–454
BCR-ABL fusion protein in, 452,
457
BCR-ABL kinase, 449, 453
clonal evolution, 449, 453
cytogenetic abnormalities in, 452,
456
dasatinib, 450, 454
hematologic stem cell
transplantation in, 457
imatinib therapy in, 449, 450,
453, 454
Iso-17q, 452, 456
nilotinib, 450, 454
regimens for disease-free survival
in, 526, 531
relapse of, 449, 453
Sokal score, 453
tyrosine kinase inhibitors in, 450,
454, 457
Chronic portal bacteremia,
cholangiocarcinoma and, 253
Chronic postradiation brachial
plexopathy, 563, 569
CI.SeeConfidence interval (CI)
Cigarette smoking
carcinogenicity and, 44
cervical cancer and, 39, 51
lung cancer and, 33, 43, 72, 76
malignant peritoneal
mesothelioma and, 489
pancreatic cancer and, 243, 247
CIN.SeeCervical intraepithelial
neoplasia (CIN)
Cinacalcet (Sensipar), 361CINV.SeeChemotherapy-induced
nausea and vomiting (CINV)
Circulating tumor cells (CTC), 23,
31
DARC and, 23, 31
nitric oxide and, 23, 31
shear forces and, 23, 31
Cisplatin, 87, 92, 125, 131, 198
for NSCLC treatment, 206, 211,
213
for SCLC treatment, 207, 211
Cisplatin-based multiagent
chemotherapy, in bladder
cancer, 281, 290
CK-7.SeeCytokeratin 7 (CK-7)
C-kit
Imatinib and, 98, 102
in seminoma, 297, 301
CLA.SeeCutaneous T-cell antigen
(CLA)
Classic Hodgkin’s lymphoma
(cHL), 422
with follicular lymphoma, 423,
434
Clear cell carcinoma and thymic
carcinoma, 218, 225
Clear cell histology
hypercalcemia and, 314
IL-2 and, 108, 112
Clear cell renal carcinoma and
VHL, 47
Clinical equipoise, 582, 585
Clinical trial
Bayesian methods in, 187, 193
censoring, 189, 194
on human subjects, ethical
requirements of, 581, 585
intention-to-treat analysis, 188,
193–194
interim analysis, 188, 194
phase II, 184, 191
phase III, 186, 192
phase I, on cytotoxic agents, 183,
191
phase 0 trials, 189, 194
power and hypothesis testing in,
186, 193
randomized treatment
assignment, 186, 192–193
sample size of, 183, 191
survival data analysis, 189, 194
therapeutic equivalence trial, 187,
193
CLL.SeeChronic lymphocytic
leukemia (CLL)
Clofarabine, 441, 446
Clonorchis sinensis, 285, 293
CML.SeeChronic myeloid
leukemia (CML)CMP.SeeComprehensive metabolic
panel (CMP)
CMV colitis, 535
CMV disease, prevention of, 545
CMV infections, 541, 547
after allogeneic HCT
manifestations of, 528, 535
risk of, 528, 533–534
CMV retinitis, 535
C-myc amplification, in small cell
lung cancer, 4, 11
C-myc promoter, 52
CNS.SeeCentral nervous system
(CNS)
Coagulase-negative staphylococci,
162(^60) Cobalt teletherapy unit, 86, 91
Coenzyme Q10 supplements, use
of, 591, 595
Cold agglutinin disease, 519, 523
Colon cancer, 23, 31
CDX2 and, 161, 170
COX-2 inhibitor and, 42, 54
KRAS mutation testing in, 123,
129
Lynch syndrome and, 45, 153,
159
MMR protein expression in, 123
relapses in early-stage, 97, 101
risk and obesity, 62, 68
treatment, oxaliplatin with 5FU
for, 270, 275
UGT1A1∗28 testing in, 123
Colonoscopy, in colorectal cancer,
269, 274–275
Colonoscopy screening, 150, 155
Color Doppler, 176
Colorectal adenoma, 138
Colorectal cancer
ablative therapy for liver
metastases in, 511, 514
alcohol consumption and, 61, 67
bevacizumab, 273, 277
cetuximab, 98, 103
colonoscopy for, 269, 274–275
CT colography of, 168, 180
FAP and, 137, 140
fecal occult blood testing in, 142,
146
FOLFOX and FOLFIRI in, 273,
277
K-RAS mutation and, 272, 277
MRI of, 168, 180
MSI and, 269, 272, 274, 277
NSAID in, 136, 139
panitumumab, 273, 277
red meat consumption and, 62, 67
treatment, cetuximab in, 97, 102
TRUS of, 168, 180